Accord Healthcare has launched Zubsolv®, an addiction-focused treatment. Zubsolv® is a sublingual tablet, containing the active substances buprenorphine and naloxone and Accord will launch five strengths across the range (1.4 / 0.36 mg, 2.9 /0.71 mg, 5.7 / 1.4 mg, 8.6 / 2.1 mg & 11.4 / 2.9 mg). This medicine is used to treat dependence on opioid drugs such as heroin or morphine in adults and adolescents over 15 years of age, who have agreed to be treated for their addiction and are also receiving medical, social and psychological support.
The Misuse of Drugs Regulations 2017 provides access to certain buprenorphine-based medicinal products in the opioid substitution treatment (including buprenorphine/naloxone and buprenorphine only) on the same statutory basis as methadone. Accord’s Zubsolv® will be available under this programme and through United Drug.
For further information please contact Accord in Cork on 021 461 9040. The SPC will be available from the Health Products Regulatory Authority website www.hpra.ie and for Healthcare Professionals on the Accord Healthcare website www.accord-healthcare.ie.
Highlighted Articles
